Skystar Bio-Pharma (SKBI) Reports Q2 EPS of $0.37

Skystar Bio-Pharma (NASDAQ: SKBI) reported Q2 EPS of $0.37, versus $0.49 reported last year. Revenue for the quarter came in at $14.2 million, versus $11.3 million reported last year.

For earnings history and earnings-related data on Skystar Bio-Pharma (SKBI) click here.

You May Also Be Interested In

• Piper Sandler sees Google TPU sales hitting $104BN by 2028
• AAR agrees to buy 65% stake in MRO Holdings for $4 billion
• Jefferies Financial Group (JEF) Tops Q3 EPS by 8c